Answers are grounded in this paper and cite their sources.
The demethylating agent azacitidine (AZA) is currently the standard of care for patients with higher-risk myelodysplastic syndromes (MDS) not eligible for allogeneic stem cell transplant (HSCT). Although approximately 50% of patients show a response to AZA it is not currently possible to accurately
No takes yet. Share an insight, caveat, or question.
Müller‐Thomas et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: